Elucidation of activation mechanism of insulin-like growth factor and development of therapy using neutralizing antibody in the gastrointestinal cancers
阐明胰岛素样生长因子的激活机制并开发使用中和抗体治疗胃肠道癌症的疗法
基本信息
- 批准号:23590939
- 负责人:
- 金额:$ 3.16万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2011
- 资助国家:日本
- 起止时间:2011 至 2013
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
It is necessary for the cancer cells to adapt to the tissue microenvironment for the metastasis formation in other ogans. Colon cancer cells highly metastasize to the liver and control of liver metastasis is most important issue in the therapeutic strategy of colon cancer. We clarified that liver-derived insulin-like growth factors (IGFs) activated by cancer-producing protease play an important role for the liver metastasis formation and could be a therapeutic target using neutralizing antibody. Furthermore, we developed the measurement system of activted (bioactive) IGF in the blood and demonstrated that bioactive IGF was increased with progressio of liver metastais and could be a biomarker of IGF neutralizing strategy in the mouse model.
癌细胞有必要适应其他OGAN中的转移形成的组织微环境。在结肠癌治疗策略中,结肠癌细胞高度转移至肝脏转移是最重要的问题。我们澄清说,通过癌症产生蛋白酶激活的肝脏衍生的胰岛素样生长因子(IGF)对肝转移的形成起着重要作用,并且可以使用中和抗体成为治疗靶标。此外,我们开发了血液中激活(生物活性)IGF的测量系统,并证明随着肝转移的进度,生物活性IGF增加了,并且可能是小鼠模型中IGF中和策略的生物标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy
- DOI:10.1007/s00280-011-1633-9
- 发表时间:2011-07-01
- 期刊:
- 影响因子:3
- 作者:Horimatsu, Takahiro;Miyamoto, Shin'ichi;Chiba, Tsutomu
- 通讯作者:Chiba, Tsutomu
Multimodal endoscopic treatment for delayed severe esophageal stricture caused by incomplete stent removal
多模态内镜治疗支架取出不全所致迟发性严重食管狭窄
- DOI:10.1111/dote.12041
- 发表时间:2014
- 期刊:
- 影响因子:2.6
- 作者:Setoyma T;Miyamoto S;Horimatsu T;Morita S;Ezoe Y;Muto M;Watanabe G;Tanaka E;Chiba T
- 通讯作者:Chiba T
An unusual cause of dysphagia after endoscopic resection of an early esophageal cancer
早期食管癌内镜切除术后吞咽困难的一个不寻常原因
- DOI:10.1055/s-0030-1256260
- 发表时间:2011
- 期刊:
- 影响因子:9.3
- 作者:Nakanishi Y;Miyamoto S;Ishizu S;Seno H;Muto M;Chiba T
- 通讯作者:Chiba T
Early Detection of 5-FU-induced Acute Leukoencephalopathy on Diffusion-Weighted MRI
- DOI:10.1093/jjco/hyq157
- 发表时间:2011-01-01
- 期刊:
- 影响因子:2.4
- 作者:Akitake, Reiko;Miyamoto, Shin'ichi;Chiba, Tsutomu
- 通讯作者:Chiba, Tsutomu
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MIYAMOTO Shin'ichi其他文献
MIYAMOTO Shin'ichi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
複数のがん分子標的治療薬の効果を左右する薬剤耐性・感受性規定因子の統合的研究
影响多种癌症分子靶向治疗药物有效性的耐药、敏感决定因素的综合研究
- 批准号:
21K07226 - 财政年份:2021
- 资助金额:
$ 3.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a diagnostic platform for precision oncology by applying reverse-phase phosphoprotein array to an analysis of formalin-fixed paraffin-embedded (FFPE) tissue
通过应用反相磷蛋白阵列分析福尔马林固定石蜡包埋 (FFPE) 组织,开发精准肿瘤学诊断平台
- 批准号:
20K07690 - 财政年份:2020
- 资助金额:
$ 3.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of Rho paradox aiming at development of molecular target drug.
阐明Rho悖论,旨在开发分子靶向药物。
- 批准号:
19K07695 - 财政年份:2019
- 资助金额:
$ 3.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of the resistance mechanisms to molecular-targeting anticancer agents
分子靶向抗癌药物耐药机制分析
- 批准号:
18K07302 - 财政年份:2018
- 资助金额:
$ 3.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Monomerization of dimerized oncogenic fusion proteins by mimetic peptides as cancer treatments
通过模拟肽对二聚化致癌融合蛋白进行单体化作为癌症治疗
- 批准号:
18K15300 - 财政年份:2018
- 资助金额:
$ 3.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists